In Vitro Fluconazole and Voriconazole Susceptibilities of Candida Bloodstream Isolates in Korea: Use of the CLSI and EUCAST Epidemiological Cutoff Values

Min Joong Jang, M.D.1, Jong Hee Shin, M.D.1, Wee Gyo Lee, M.D.2, Mi-Na Kim, M.D.3, Kyungwon Lee, M.D.4, Hye Soo Lee, M.D.5, Mi-Kyung Lee, M.D.5, Chulhun L. Chang, M.D.2, Hee-Chang Jang, M.D.1, Eun Song Song, M.D.1, Soo Hyun Kim, M.D.1, Myung-Geun Shin, M.D.1, Soon-Pal Suh, M.D.1, and Dong-Wook Ryang, M.D.1
Department of Laboratory Medicine1, Chonnam National University Medical School and Chonnam National University Hospital, Gwangju; Department of Laboratory Medicine2, Ajou University, Suwon; Department of Laboratory Medicine3, University of Ulsan College of Medicine and Asan Medical Center, Seoul; Department of Laboratory Medicine4, Yonsei University College of Medicine, Seoul; Department of Laboratory Medicine5, Chonbuk National University Medical School, Jeonju; Department of Laboratory Medicine6, Chung-Ang University College of Medicine, Seoul; Department of Laboratory Medicine7, Pusan National University College of Medicine, Busan, Korea

Background: At present, the clinical breakpoints (CBPs) of both fluconazole and voriconazole are available only for 3 common Candida species in the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) methods. Epidemiological cutoff values (ECVs) were recently applied to both methods to detect the emergence of acquired resistance (i.e., non-wild-type isolates) among 5 common Candida species.

Methods: We performed a nationwide study to determine the fluconazole and voriconazole susceptibility of Candida bloodstream isolates (BSIs) using both the CLSI and EUCAST methods. A total of 423 BSIs of 5 Candida species were collected from 8 hospitals. The azole susceptibilities were assessed on the basis of the species-specific CBPs and ECVs.

Results: Of the 341 BSIs of 3 common Candida species (i.e., C. albicans, C. tropicalis, and C. parapsilosis), 0.3% and 0.9%, 0.0% and 1.5% of isolates were categorized as fluconazole and voriconazole resistant according to the CLSI and EUCAST CBPs, respectively. Of 423 total BSIs, 1.4% and 2.6% had fluconazole minimum inhibitory concentrations (MICs) exceeding the ECVs according to the CLSI and EUCAST, respectively; 1.0% and 2.1% had voriconazole MICs exceeding the ECVs according to the CLSI and EUCAST, respectively. Categorical agreement between the methods using ECVs was 98.3% for fluconazole and 98.3% for voriconazole.

Conclusions: The EUCAST and CLSI methods using ECVs provide highly concordant results. Moreover, non-wild-type isolates with possibly acquired azole resistance were rare among the BSIs of 5 common Candida species in Korea.

Key Words: Candida, Fluconazole, Voriconazole, EUCAST, CLSI, epidemiological cutoff value

INTRODUCTION

Antifungal susceptibility testing against Candida is now recognized as a useful aid in patient management and resistance surveillance [1-3]. There are 2 independent standards for antifungal susceptibility testing against Candida: the broth microdilution (BMD) method developed by the Clinical and Laboratory Standards Institute (CLSI) in the United States and the BMD
method of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) in Europe [4, 5]. These 2 methods are similar in that both use the BMD, while they differ in terms of inoculum size and minimum inhibitory concentration (MIC) endpoint determination [1]. Although both the CLSI and EUCAST have established clinical breakpoints (CBPs) for fluconazole and voriconazole, the EUCAST CBPs are species specific and apply only to Candida albicans, Candida tropicalis, and Candida parapsilosis [1, 6, 7]. The CLSI is currently revising CBPs for different Candida species [1-3]. The originally proposed CLSI CBPs were not species specific, and assigned values for the susceptibility to ≤8 μg/mL fluconazole and ≤1 μg/mL voriconazole were applied to all Candida species [4]. These CBPs are flawed in that a breakpoint is too high to provide a sensitive means of predicting the emergence of resistance among more susceptible species such as C. albicans, C. tropicalis, and C. parapsilosis and simultaneously bisects the wild-type distribution of Candida glabrata [1, 3]. Therefore, the CLSI subcommittee reconsidered the MIC distributions for each species and antifungal agent, and developed epidemiological cutoff values (ECVs); these ECV data were used in conjunction with molecular, pharmacodynamic, and clinical data to revise the CBPs to provide species-specific interpretative criteria [1-3]. ECVs may also be used to identify isolates that are less likely to respond to antimicrobial therapy because of acquired resistance mechanisms when limited clinical data preclude the development of CBPs [3].

The EUCAST first defined the wild-type (WT) MICs and ECVs for the 5 most common Candida species: C. albicans, C. tropicalis, C. parapsilosis, C. glabrata, and Candida krusei [1, 6, 7]. The WT MIC distribution is defined as the MIC distribution for isolates that exhibit no acquired or mutational resistance to the drug in question; meanwhile, non-WT isolates may possess acquired or mutational resistance mechanisms [1, 6]. The upper limit of the WT population is defined as the ECV. ECVs have recently been applied to EUCAST and CLSI antifungal susceptibility testing, and WT distributions from large collections of the 5 most common Candida species show that the CLSI and EUCAST methods yield similar ECVs [1]. While CBPs are used to identify isolates likely to respond to treatment with a given antimicrobial agent administered at its approved dosing regimen, the ECV may serve as the most sensitive measure of the emergence of strains with reduced susceptibility (i.e., acquired resistance) to that agent [3, 8, 9].

To date, no data on the antifungal susceptibility of Candida bloodstream isolates (BSIs) have been obtained using the EUCAST method or species-specific CBPs or ECVs in Korea. Therefore, we performed a multicenter study to determine the susceptibilities of Candida BSIs to fluconazole and voriconazole in Korea using both the CLSI and EUCAST methods. We also applied the species-specific CBPs and ECVs for Candida BSIs, for the first time. In addition, we compared the CLSI and EUCAST BMD methods for testing 2azole agents against Candida species using ECVs.

METHODS

1. Candida isolates

All Candida BSIs were prospectively and routinely collected from blood cultures at 8 tertiary hospitals in Korea between September 2009 and August 2010. Some Candida isolates were provided by the Chonbuk National University Hospital Culture Collection for Pathogens. Duplicate C. albicans isolates from the same patient were excluded. Species identification and antifungal susceptibility testing of the Candida isolates were performed at Chonnam National University Hospital. Speciation was based on colony morphology on CHROMagar Candida (BBL, Becton Dickinson, Sparks, MD, USA) at 35°C and a commercially available biochemical identification system (API 20C or Vitek 2 ID-YST; bioMérieux, Marcy L’Etoile, France). During the study period, a total of 440 Candida BSIs were collected from the 8 hospitals. Of these, 423 (96.1%) were the 5 most-common Candida species and were evaluated: 170 C. albicans, 93 C. tropicalis, 79 C. glabrata, 78 C. parapsilosis, and 3 C. krusei isolates).

2. Antifungal susceptibility testing

In vitro fluconazole and voriconazole susceptibility testing was performed on all isolates using both the CLSI and EUCAST BMD methods. The CLSI BMD method was performed according to document M27-3 using RPMI 1640 medium containing 0.165 M MOPS, an inoculum of 0.5-2.5×10^6 cells/L, and incubation at 35°C [4]. In the CLSI method, the MICs were determined visually 24 hr after incubation as the lowest concentration of a drug that caused ≥50% inhibition in growth compared to control levels. The recently revised CLSI CBPs were used to identify Candida strains resistant to fluconazole and voriconazole. A fluconazole MIC ≤2 μg/mL was considered susceptible, 4 μg/mL was considered susceptible dose dependent (SDD), and ≥8 μg/mL was considered resistant for C. albicans, C. parapsilosis, and C. tropicalis; a fluconazole MIC ≤32 μg/mL was considered SDD, while ≥64 μg/mL was considered resistant for C. glabrata; a voriconazole MIC ≤0.12 μg/mL was considered susceptible, 0.25-0.5 μg/mL was considered intermedi-
ate, and ≥1 μg/mL was considered resistant for *C. albicans*, *C. parapsilosis*, and *C. tropicalis*; a voriconazole MIC ≤0.5 μg/mL was considered susceptible, 1 μg/mL was considered intermediate, and ≥2 μg/mL was considered resistant for *C. krusei* [1-3].

EUCAST BMD testing was performed as described in document EDef 7.1 using RPMI 1640 medium containing 2.0% glucose, an inoculum of 0.5-2.5×10^6 cells/L, and incubation at 35°C [5]. MICs were determined as the lowest concentration of drug that resulted in ≥50% inhibition of growth compared to control levels spectrophotometrically at 530 nm after incubation for 24 hr. Interpretative breakpoints proposed by the EUCAST for fluconazole (susceptible, ≤2 μg/mL; resistant, >4 μg/mL) and voriconazole (susceptible, ≤0.125 μg/mL; resistant, >0.125 μg/mL) were used for only *C. albicans*, *C. parapsilosis*, and *C. tropicalis* [6, 7]. Two reference strains, *C. parapsilosis* ATCC 22019 and *C. krusei* ATCC 6258, were used as quality-control isolates in each antifungal susceptibility test.

3. Comparison of the CLSI and EUCAST methods
The fluconazole and voriconazole MIC results obtained by the EUCAST method were compared to those obtained by CLSI M27 BMD after incubation for 24 hr. Essential agreement was defined when the MICs from the 2 methods were within 2 dilutions (i.e., 2 wells) of each other. Categorical agreement was obtained on the basis of the recently described fluconazole and voriconazole ECVs for the CLSI-24 hr (0.5 and 0.03 μg/mL for *C. albicans*, 2 and 0.12 μg/mL for *C. parapsilosis*, 2 and 0.06 μg/mL for *C. tropicalis*, 32 and 0.5 μg/mL for *C. glabrata*, and 64 and 0.5 μg/mL for *C. krusei*, respectively) [1, 3] and EUCAST (1 and 0.12 μg/mL for *C. albicans*, 2 and 0.12 μg/mL for *C. parapsilosis*, 2 and 0.12 μg/mL *C. tropicalis*, 32 and 0.5 μg/mL for *C. glabrata*, and 128 and 1 μg/mL for *C. krusei*, respectively) [6, 7]. Isolates with MICs less than or equal to the respective ECVs were termed susceptible WT isolates, while the others were considered resistant non-WT isolates [1, 8, 9]. Discrepancies were considered to be very major when an isolate classified as non-WT by the CLSI ECV was categorized as WT by the EUCAST ECV and major when an isolate classified as WT by the CLSI ECV was classified as non-WT by the EUCAST ECV.

RESULTS
Table 1 summarizes the *in vitro* susceptibilities of 423 BSIs of 5 *Candida* species to fluconazole and voriconazole as determined by the CLSI and EUCAST BMD methods. For all 423 BSIs, the antifungal MIC ranges determined by the CLSI and EUCAST methods were similar: 0.125-64 μg/mL and 0.125-128 μg/mL for fluconazole and 0.03-2 μg/mL and 0.03-4 μg/mL for voriconazole, respectively. For most isolates, the fluconazole and voriconazole MICs obtained by the EUCAST method tended to be one twofold dilution higher than those obtained by the CLSI method. The overall rates of essential agreement (i.e., within 2 dilutions) between the CLSI and EUCAST MIC results were 97.6% for fluconazole and 98.3% for voriconazole. Of the 341 BSIs of the 3 most common species (*C. albicans*, *C. tropicalis*, and *C. parapsilosis*), only 3 (0.9%) and 5 (1.5%) were resistant to fluconazole (MIC ≥8 μg/mL), and voriconazole (MIC ≥0.25 μg/mL) according to the EUCAST method, respectively, and 1 (0.3%) and 0 (0.0%) isolates were resistant to voriconazole (MIC ≥8 μg/mL) and voriconazole (MIC ≥1 μg/mL) according to the CLSI method, respectively. Of the 79 *C. glabrata* isolates, only 3 (3.8%) were fluconazole resistant (MIC ≥64 μg/mL), while the remaining 76 (96.2%) were SDD (MIC ≤32 μg/mL) according to the CLSI.

Table 2 shows categorical agreement between the results of the CLSI and EUCAST BMD methods for fluconazole and voriconazole using the ECVs. When the species-specific fluconazole ECVs were applied, the percentages of non-WT isolates determined by the CLSI and EUCAST methods were 0.6% and 0.0% for *C. albicans*, 0.0% and 2.2% for *C. tropicalis*, 3.8% and 5.1% for *C. glabrata*, 2.6% and 6.4% for *C. parapsilosis*, and 0.0% and 0.0% for *C. krusei*, respectively. In addition, the percentages of non-WT isolates with voriconazole MICs exceeding the ECVs according to the CLSI and EUCAST BMD methods were 0.0% and 0.0% for *C. albicans*, 0.0% and 4.3% for *C. tropicalis*, 5.1% and 5.1% for *C. glabrata*, 0.0% and 1.4% for *C. parapsilosis*, and 0.0% and 0.0% for *C. krusei*, respectively. Overall, when applying species-specific ECVs, 1.4% and 2.6% of isolates were categorized as fluconazole-resistant non-WT isolates (i.e., exceeding the ECVs) by the CLSI and EUCAST BMD methods, respectively; meanwhile, 1.0% and 2.1% were categorized as voriconazole-resistant non-WT isolates, respectively. The percentages of categorical agreement between the CLSI and EUCAST methods was 98.3% for fluconazole and 98.3% for voriconazole. The overall rates of categorical discrepancies between the EUCAST and CLSI methods were 1.6% for fluconazole (very major errors, 0.2%; major errors, 1.4%) and 1.7% for voriconazole (very major errors, 0.0%; major errors, 1.7%).

DISCUSSION
The CLSI and EUCAST have both published ECVs for the 5 most
common Candida species against fluconazole and voriconazole; they are currently revising their species-specific CBPs for several antifungal agents and various Candida species to further harmonize both methods [1-3]. Although revised species-specific CBPs for both fluconazole and voriconazole are not available for less common Candida species at present, the CLSI has proposed revised CBPs for 3 common Candida species by utilizing molecular, microbiologic, pharmacodynamic, and clinical data [3]. The EUCAST CBPs also apply only to 3 common Candida species [6, 7]. When CBPs are unavailable, ECVs can be applied to local and global antifungal surveillance studies to detect the emergence of antifungal resistance among Candida species [3, 8, 9]. The present study is the first to compare EUCAST and CLSI MIC results for BSIs of 5 common Candida species from 8 hospitals in Korea and determine the fluconazole and voriconazole susceptibilities of Candida BSIs in Korea using species-specific CBPs and ECVs.

In the present study, only 1 (0.3%) isolate of 3 common Candida species (i.e., C. albicans, C. tropicalis, and C. parapsilosis) was categorized as fluconazole resistant on the basis of the revised CLSI CBPs; none were categorized as voriconazole resistant. Meanwhile, only 3 (0.9%) and 5 (1.5%) isolates were resistant to fluconazole and voriconazole, respectively, according to the EUCAST method. Several global surveillance programs used...
Table 2. Categorical agreement between the results of the CLSI and EUCAST BMD methods for fluconazole and voriconazole and Candida species based on ECVs

| Species (N of isolates tested) | Antifungal agent | Test method | ECV* (µg/mL) | N of isolates (%) with indicated results: | Categorical agreement (%) | % of categorical discrepancies† |
|------------------------------|-----------------|-------------|--------------|-----------------------------------------|--------------------------|-------------------------------|
|                              |                 |             | ≤ ECV | > ECV | VM | M |
| C. albicans (170)            | Fluconazole     | CLSI        | 0.5   | 169 (99.4) | 1 (0.6)   | 99.4 | 0.6 | 0.0 |
|                              | Fluconazole     | EUCAST      | 1     | 170 (100.0) | 0 (0.0)   | 100.0 | 0.0 | 0.0 |
|                              | Voriconazole    | CLSI        | 0.03  | 170 (100.0) | 0 (0.0)   | 100.0 | 0.0 | 0.0 |
|                              | Voriconazole    | EUCAST      | 0.12  | 170 (100.0) | 0 (0.0)   | 100.0 | 0.0 | 0.0 |
| C. tropicalis (93)           | Fluconazole     | CLSI        | 2     | 93 (100.0)  | 0 (0.0)   | 100.0 | 0.0 | 0.0 |
|                              | Fluconazole     | EUCAST      | 2     | 91 (97.8)   | 2 (2.2)   | 97.8  | 0.0 | 2.2 |
|                              | Voriconazole    | CLSI        | 0.06  | 93 (100.0)  | 0 (0.0)   | 100.0 | 0.0 | 0.0 |
|                              | Voriconazole    | EUCAST      | 0.12  | 89 (95.7)   | 4 (4.3)   | 95.7  | 0.0 | 4.3 |
| C. glabrata (79)             | Fluconazole     | CLSI        | 32    | 76 (96.2)   | 3 (3.8)   | 96.2  | 0.0 | 3.8 |
|                              | Fluconazole     | EUCAST      | 32    | 75 (94.9)   | 4 (5.1)   | 98.7  | 0.0 | 1.3 |
|                              | Voriconazole    | CLSI        | 0.5   | 75 (94.9)   | 4 (5.1)   | 98.7  | 0.0 | 1.3 |
|                              | Voriconazole    | EUCAST      | 1     | 75 (94.9)   | 4 (5.1)   | 97.5  | 0.0 | 2.5 |
| C. parapsilosis (78)         | Fluconazole     | CLSI        | 2     | 76 (97.4)   | 2 (2.6)   | 96.2  | 0.0 | 3.8 |
|                              | Fluconazole     | EUCAST      | 2     | 73 (93.5)   | 5 (6.4)   | 98.7  | 0.0 | 1.3 |
|                              | Voriconazole    | CLSI        | 0.12  | 78 (100.0)  | 0 (0.0)   | 100.0 | 0.0 | 0.0 |
|                              | Voriconazole    | EUCAST      | 0.12  | 77 (98.7)   | 1 (1.4)   | 98.7  | 0.0 | 1.2 |
| C. krusei (3)                | Fluconazole     | CLSI        | 64    | 3 (100.0)   | 0 (0.0)   | 100.0 | 0.0 | 0.0 |
|                              | Fluconazole     | EUCAST      | 128   | 3 (100.0)   | 0 (0.0)   | 100.0 | 0.0 | 0.0 |
|                              | Voriconazole    | CLSI        | 0.5   | 3 (100.0)   | 0 (0.0)   | 100.0 | 0.0 | 0.0 |
|                              | Voriconazole    | EUCAST      | 1     | 3 (100.0)   | 0 (0.0)   | 100.0 | 0.0 | 0.0 |
| Total (423)                  | Fluconazole     | CLSI        | 417   | 6 (1.4)     | 411 (98.6)| 98.6 | 0.2 | 1.4 |
|                              | Fluconazole     | EUCAST      | 412   | 11 (2.6)    | 411 (97.4)| 97.4 | 0.0 | 2.6 |
|                              | Voriconazole    | CLSI        | 419   | 4 (1.0)     | 415 (99.0)| 99.0 | 0.2 | 1.4 |
|                              | Voriconazole    | EUCAST      | 414   | 9 (2.1)     | 405 (97.9)| 97.9 | 0.0 | 2.1 |

*The ECVs of CLSI and EUCAST were obtained from references [1, 3, 6, 7]; †VM, very major discrepancies when an isolate classified as non-wild type (above ECV) by the CLSI ECV was categorized as wild type by the EUCAST ECV; M, major discrepancies when an isolate classified as wild type by the CLSI ECV was classified as non-wild type by the EUCAST ECV.

Abbreviations: CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; BMD, broth microdilution; ECV, epidemiological cutoff value.

ing CBPs also demonstrate that the majority of BSIs of 3 common Candida species are susceptible to fluconazole and voriconazole [10-13]. However, a recent study indicates a slight but consistent increase in possible resistance to fluconazole and voriconazole among non-WT isolates of 3 common Candida species according to the EUCAST and CLSI ECVs [8]. Although Candida isolates for which theazole MICs exceed the ECV may still respond to clinical treatment as the MIC may lie below the CBP, ECVs can be a sensitive measure for detecting the emergence of Candida strains with decreased fluconazole and voriconazole susceptibility [1-3].

To date, few comparative studies of CLSI and EUCAST antifungal data obtained using ECVs have been performed, except one international study by Pfaller et al. [14]. This global multicenter study determined the rates of non-WT isolates among 1,056 clinical isolates of 5 common Candida species to be 3.0% and 5.5% for fluconazole and 2.6% and 4.3% for voriconazole on the basis of ECVs determined by the CLSI and EUCAST methods, respectively. In the present study, the prevalence of non-WT isolates was 1.4% and 2.6% using fluconazole ECVs determined by the CLSI and EUCAST BMD methods, respectively, and 1.0% and 2.1% using voriconazole ECVs, respec-
tively. These results show that the prevalence of non-WT BSIs of Candida species in Korea remains lower than that in other geographic regions. Pfaller et al. [15, 16] report that the prevalence of azole resistance among Candida isolates is variable both over time and by country and region. Although the prevalence of azole resistance among Candida species is not entirely related to antifungal drug pressure, our previous study provides the first evidence that increased fluconazole use can be significantly correlated with an increased number of fluconazole non-susceptible Candida isolates from clinical specimens [17].

C. glabrata is innately less susceptible to azoles than most other Candida species and rapidly acquires secondary azole resistance following exposure to fluconazole [18, 19]. The azole resistance frequency among C. glabrata BSIs may impact the empiric antifungal therapy choice [15]. The EUCAST has refrained from assigning CBPs for fluconazole and voriconazole to C. glabrata and advises alternative drugs to manage infections caused by this species [6, 7]. In contrast to the EUCAST, the CLSI recently revised the CBPs for fluconazole and C. glabrata to <32 μg/mL for SDD and ≥64 μg/mL for resistant with the caveat that a maximum dose of fluconazole of 800 mg/day (12 mg/kg/day) be used when treating C. glabrata infections with fluconazole [3]. When the new CLSI CBPs were applied to the 79 C. glabrata isolates in the present study, 3 (3.8%) and 76 (96.2%) were resistant and SDD to fluconazole, respectively. In a previous global multicenter study, the prevalence of non-WT C. glabrata isolates according to the ECVs determined by the CLSI and EUCAST methods was 6.9% and 9.7% for fluconazole and 9.1% and 15.4% for voriconazole, respectively [14]. In the present study, the prevalence of non-WT C. glabrata isolates according to the ECVs determined by the CLSI and EUCAST methods was 3.8% and 5.1% for fluconazole and 5.1% and 5.1% for voriconazole, respectively. These results show that the azole resistance rates of C. glabrata BSIs in Korea remain lower than those in other geographic regions.

Similar to the present study, the global multicenter study by Pfaller et al. [14] demonstrates excellent essential agreement between the CLSI and EUCAST results with respect to susceptibility to fluconazole (98.6% within 2 dilutions) and voriconazole (96.9%). Our data indicate excellent categorical agreement between the CLSI and EUCAST BMD methods for all 5 Candida species for both fluconazole (98.3%) and voriconazole (98.3%). Pfaller et al. [14] also observed excellent categorical agreement (96%) for all comparisons between the CLSI and EUCAST methods for all Candida species except C. parapsilosis (90.8% categorical agreement; 0.6% very major discrepancies). In their study, the prevalence of fluconazole resistance among C. parapsilosis isolates was relatively high (17.9% and 9.9% determined by the EUCAST and CLSI methods, respectively). In the present study, the categorical agreement between the CLSI and EUCAST methods for C. parapsilosis was 96.2% and the prevalence of resistant non-WT C. parapsilosis isolates determined by the CLSI and EUCAST methods was 6.4% and 2.6%, respectively. Therefore, the high categorical agreement in the present study may be due in part to the low frequency of fluconazole resistance in our collection of BSIs of 5 Candida species common in Korea.

In conclusion, our data shows that the EUCAST and CLSI methods using ECVs provide highly concordant results for fluconazole and voriconazole susceptibility in 5 Candida species. Furthermore, the results suggest ECVs are sensitive for detecting the emergence of fluconazole and voriconazole resistance in these Candida species. When we examined the fluconazole and voriconazole susceptibilities of 5 major Candida BSIs using the ECVs, the rates of resistance were found to be low.

**Authors’ Disclosures of Potential Conflicts of Interest**

No potential conflicts of interest relevant to this article were reported.

**Acknowledgement**

This work was supported by a grant (CRI11082) Chonnam National University Hospital Research Institute of Clinical Medicine.

**REFERENCES**

1. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010;13:180-95.
2. Pfaller MA, Andes D, Arendrup MC, Diekema DJ, Espinel-Ingroff A, Alexander BD, et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 2011;70:330-43.
3. Pfaller MA and Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 2012;50:2846-56.
4. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. 3rd ed, M27-A3. Wayne, PA: Clinical and Laboratory Standards Insti-
5. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008;14:398-405.

6. European Committee on Antimicrobial Susceptibility Testing, Subcommittee on Antifungal Susceptibility Testing, EUCAST technical note on fluconazole. Clin Microbiol Infect 2008;14:193-5.

7. European Committee on Antimicrobial Susceptibility Testing, Subcommittee on Antifungal Susceptibility Testing, EUCAST technical note on voriconazole. Clin Microbiol Infect 2008;14:985-7.

8. Rambach G, Oberhauser H, Speth C, Lass-Flörl C. Susceptibility of Candida species and various moulds to antymycotic drugs: use of epidemiological cutoff values according to EUCAST and CLSI in an 8-year survey. Med Mycol 2011;49:856-63.

9. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida. J Clin Microbiol 2011;49:3800-4.

10. Jung SI, Shin JH, Song JH, Peck KR, Lee K, Kim MN, et al. Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea. Med Mycol 2010;48:669-74.

11. Pfaller MA and Diekema DJ. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004;10: S11-23.

12. Pfaller MA and Diekema DJ. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole and Candida: time for new clinical breakpoints? Curr Fungal Infect Rep 2010;4:168-74.

13. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006;27:359-66.

14. Pfaller MA, Espinel-Ingroff A, Boyken L, Hollis RJ, Kroeger J, Messer SA, et al. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values. J Clin Microbiol 2011;49:845-50.

15. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Barton R, Bijie H, et al. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2010;67:162-71.

16. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007;45:1735-45.

17. Kim SH, Shin JH, Kim EC, Lee K, Kim MN, Lee WG, et al. The relationship between antifungal usage and antifungal susceptibility in clinical isolates of Candida: a multicenter Korean study. Med Mycol 2009;47:296-304.

18. Shin JH, Chae MJ, Song JW, Jung SI, Cho D, Kee SJ, et al. Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia. J Clin Microbiol 2007;45:2385-91.

19. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother 2005;49:668-79.